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Cardiovascular diseases (CVD) are the leading causes of death and dis-
ability in the developed world1, with an increasing prevalence due to
the aging of the population and the obesity epidemic. More than 
1 million deaths in the US alone were caused by myocardial infarction
and stroke in 2003 (ref. 2). Some of the processes underlying myocar-
dial infarction are now understood: it is generally attributed to athero-
sclerosis with arterial wall inflammation that ultimately leads to
plaque rupture, fissure or erosion3,4. This process is known to involve
diapedesis of monocytes across the endothelial barrier; activation of
neutrophils, macrophage cells and platelets; and release of a variety of
cytokines and chemokines5,6, but the genetic basis of the process has
not yet been deciphered.
Two different approaches have been used to search for genes associ-
ated with myocardial infarction. SNPs in candidate genes have been
tested for association and have, in general, not been replicated or con-
fer only a modest risk of myocardial infarction. Case-control associa-
tion studies have identified several proinflammatory genes with
variants that are associated with either an increased risk of myocardial
infarction or a protective effect7–9. Four genome-wide scans in families
with myocardial infarction have yielded several loci with formidable
linkage peaks, but the gene(s) underlying these loci have not yet been
identified10–14. In addition, one large pedigree study identified a dele-
tion mutation of a transcription factor gene, MEF2A, with autosomal
dominant transmission14. This is an interesting cause of myocardial
infarction, but the prevalence of this or other mutations in MEF2A
outside this family remains to be determined.
Here we report a genome-wide scan of 296 multiplex Icelandic
families including 713 individuals with myocardial infarction.
Through suggestive linkage to a locus on chromosome 13q12–13, we
identified the gene (ALOX5AP) encoding FLAP and found that a
four-SNP haplotype in the gene confers a nearly two times greater
risk of myocardial infarction and stroke. FLAP is a regulator15 of a
crucial pathway in the genesis of leukotriene inflammatory media-
tors, which are implicated in atherosclerosis both in a mouse
model16 and in human studies17,18. Males had the strongest associa-
tion to the at-risk haplotype, and male carriers of the at-risk haplo-
type also had significantly greater production of leukotriene-B4
(LTB4), supporting the idea that proinflammatory activity has a role
in the pathogenesis of myocardial infarction. We confirmed the asso-
ciation of ALOX5AP with myocardial infarction in an independent
cohort of British individuals with another haplotype. These results
indicate that ALOX5AP is the first specific gene isolated that confers
substantial population-attributable risk (PAR) of the complex traits
of both myocardial infarction and stroke.
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The gene encoding 5-lipoxygenase activating protein
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We mapped a gene predisposing to myocardial infarction to a locus on chromosome 13q12–13. A four-marker single-nucleotide
polymorphism (SNP) haplotype in this locus spanning the gene ALOX5AP encoding 5-lipoxygenase activating protein (FLAP) is
associated with a two times greater risk of myocardial infarction in Iceland. This haplotype also confers almost two times greater
risk of stroke. Another ALOX5AP haplotype is associated with myocardial infarction in individuals from the UK. Stimulated
neutrophils from individuals with myocardial infarction produce more leukotriene B4, a key product in the 5-lipoxygenase
pathway, than do neutrophils from controls, and this difference is largely attributed to cells from males who carry the at-risk
haplotype. We conclude that variants of ALOX5AP are involved in the pathogenesis of both myocardial infarction and stroke by
increasing leukotriene production and inflammation in the arterial wall.
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RESULTS
Linkage analysis
We carried out a genome-wide scan in search of myocardial infarction
susceptibility genes using a framework set of 1,068 microsatellite
markers. The initial linkage analysis included 713 individuals with
myocardial infarction who fulfilled the World Health Organization
(WHO) MONICA research criteria19 and were clustered in 296
extended families. We repeated the linkage analysis for individuals
with early onset, for males and for females separately. A description of
the number of affected individuals and families in each analysis is
provided in Supplementary Table 1 online, and the corresponding
allele-sharing lod scores are given in Supplementary Figure 1 online.
None of these analyses yielded a locus of genome-wide significance.
The most promising lod score (2.86) was observed on chromosome
13q12–13 for linkage with females with myocardial infarction at the
peak marker D13S289 (Supplementary Fig. 1 online). This locus also
had the most promising lod score (2.03) for individuals with early-
onset myocardial infarction. After we increased the information on
identity-by-descent sharing to over 90% by typing an additional 14
microsatellite markers in a 30-cM region around D13S289, the lod
score for the association in females dropped to 2.48 (P = 0.00036),
and the lod score remained highest at D13S289 (Fig. 1a). In an inde-
pendent linkage study of males with ischemic stroke or transient
ischemic attack (TIA), we observed linkage to the same locus with a
lod score of 1.51 at the same peak marker (Supplementary Fig. 2
online), further suggesting that a cardiovascular susceptibility factor
might reside at this locus.
Microsatellite association study
The 7.6-Mb region that corresponds to a drop of 1 in lod score in the
female–myocardial infarction linkage analysis contains 40 known
genes (Supplementary Table 2 online). To determine which gene in
this region was most likely to contribute to myocardial infarction, we
typed 120 microsatellite markers in the region and carried out a case-
control association study using 802 unrelated (separated by at least
three meioses) individuals with myocardial infarction and 837 popu-
lation-based controls. We also repeated the association study for each
of the three phenotypes that were used in the linkage study: individu-
als with early onset, males and females with myocardial infarction. In
addition to testing each marker individually, we also tested haplo-
types based on these markers for association. To limit the number of
haplotypes tested, we considered only haplotypes spanning less than
300 kb that were over-represented among the affected individuals.
The haplotype with the strongest association to myocardial infarc-
tion (P = 0.00004) covered a region that contains two known genes:
ALOX5AP (Fig. 1b) and a gene with an unknown function called
highly charged protein (D13S106E). The haplotype association in this
region for females with myocardial infarction was less significant (P =
0.0004) than for all individuals with myocardial infarction, and the
most significant haplotype association was observed for males with
myocardial infarction (P = 0.000002). The haplotype associated with
males with myocardial infarction was the only haplotype that retained
significant association after adjusting for all haplotypes tested.
FLAP, together with 5-lipoxygenase (5-LO), is a regulator of the
leukotriene biosynthetic pathway that has recently been implicated in
the pathogenesis of atherosclerosis16–18. Therefore, ALOX5AP was a
good candidate for the gene underlying the association with myocar-
dial infarction.
Screening for SNPs in ALOX5AP and LD mapping
To determine whether variations in ALOX5AP significantly associate
with myocardial infarction and to search for causal variations, we
sequenced ALOX5AP in 93 affected individuals and 93 controls. The
sequenced region covers 60 kb containing ALOX5AP, including the
five known exons and introns, the 26-kb region 5′ to the first exon and
the 7-kb region 3′ to the fifth exon. We identified 144 SNPs, of which
we excluded 96 from further analysis owing to either a low minor allele
frequency or complete correlation (redundancy) with other SNPs.
Figure 1c shows the distribution of the 48 SNPs chosen for genotyp-
ing, relative to exons, introns and the 5′ and 3′ flanking regions of
ALOX5AP. We identified only one SNP in a coding sequence (exon 2),
which did not lead to an amino acid substitution. The locations of the
48 SNPs in the National Center for Biotechnology Information human
genome assembly build 34 are listed in Supplementary Table 3 online.
In addition to the SNPs, we typed a polymorphism consisting of a
monopolymer A repeat in the ALOX5AP promoter region20.
The linkage disequilibrium (LD) block structure defined by the 48
genotyped SNPs is shown in Figure 2. Strong LD was detected across
the ALOX5AP region, although at least one historical recombination
seems to have occurred, dividing the region into two strongly corre-
lated LD blocks.
Figure 1 Schematic view of the chromosome 13 linkage region showing
ALOX5AP. (a) The linkage scan for females with myocardial infarction and
the one-lod drop region that includes ALOX5AP. (b) Microsatellite
association for all individuals with myocardial infarction: single-marker
association (black dots) and two-, three-, four- and five-marker haplotype
association (black, blue, green and red horizontal lines, respectively). The
blue and red arrows indicate the location of the most significant haplotype
association across ALOX5AP in males and females, respectively. (c)
ALOX5AP gene structure, with exons shown as colored cylinders, and the
locations of all SNPs typed in the region. The green vertical lines indicate
the position of the microsatellites (b) and SNPs (c) used in the analysis.0 10 20 30 40 50cM
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Haplotype association with myocardial infarction
In a case-control association study, we genotyped the 48 selected SNPs
and the monopolymer A repeat marker in a set of 779 unrelated indi-
viduals with myocardial infarction and 624 population-based con-
trols. We tested each of the 49 markers individually for association
with the disease. Three SNPs, one located 3 kb upstream of the first
exon and the other two 1 kb and 3 kb downstream of the first exon,
showed nominally significant association to myocardial infarction
(Supplementary Table 4 online). After adjusting for the number of
markers tested, however, these results were not significant. We then
searched for haplotypes associated with the disease using the same
cohorts. We limited the search to haplotype combinations constructed
from two, three or four SNPs and tested only haplotypes that were
over-represented in the individuals with myocardial infarction. The
resulting P values were adjusted for all the haplotypes we tested by ran-
domizing the affected individuals and controls.
Several haplotypes were significantly associated with the disease at
an adjusted significance level of P < 0.05 (Supplementary Table 5
online). We observed the most significant
association with a four-SNP haplotype span-
ning 33 kb, including the first four exons of
ALOX5AP (Fig. 1c), with a nominal P value of
0.0000023 and an adjusted P value of 0.005.
This haplotype, called HapA, has a haplotype
frequency of 15.8% (carrier frequency 29.1%)
in affected individuals versus 9.5% (carrier
frequency 18.1%) in controls (Table 1). The
relative risk conferred by HapA compared
with other haplotypes constructed from the
same SNPs, assuming a multiplicative model,
was 1.8 and the corresponding PAR was
13.5%. HapA was present at a higher fre-
quency in males (carrier frequency 30.9%)
than in females with myocardial infarction
(carrier frequency 25.7%; Table 1). All other
haplotypes that were significantly associated
with an adjusted P value less than 0.05 were
highly correlated with HapA and should be considered variants of that
haplotype (Supplementary Table 5 online).
Association of HapA with stroke and PAOD
Because of  the high degree of comorbidity among myocardial infarc-
tion, stroke and peripheral arterial occlusive disease (PAOD), with
most of these cases occurring on the basis of an atherosclerotic disease,
we wanted to determine whether HapA was also associated with stroke
or PAOD. We typed the SNPs defining HapA for these cohorts. We
removed first- and second-degree relatives and all known cases of
myocardial infarction and tested for association in 702 individuals
with stroke and 577 individuals with PAOD (Table 1). We observed a
significant association of HapA with stroke, with a relative risk of 1.67
(P = 0.000095). In addition, we determined whether HapA was pri-
marily associated with a particular subphenotype of stroke and found
that both ischemic and hemorrhagic stroke were significantly associ-
ated with HapA (Supplementary Table 6 online). Finally, although
HapA was more frequent in the PAOD cohort than in the population
controls (Table 1), this was not significant. Similar to the stronger
association of HapA with males with myocardial infarction than with
females with myocardial infarction, HapA also showed stronger asso-
ciation with males than with females with stroke and PAOD (Table 1). 
Haplotype association in a British cohort
In an independent study, we determined whether variants in
ALOX5AP also affected the risk of myocardial infarction in a popula-
tion outside Iceland. We typed SNPs defining HapA in a cohort of 753
individuals from the UK who had sporadic myocardial infarction and
in 730 British population controls. The affected individuals and con-
trols were from three separate study cohorts recruited in Leicester and
Sheffield. We found a slightly higher frequency of HapA in affected
individuals versus controls (16.8% versus 15.1%, respectively), but the
results were not statistically significant. As in the Icelandic population,
HapA was more common in males with myocardial infarction (carrier
frequency 31.7%) than in females with myocardial infarction (carrier
frequency 28.0%). When we typed an additional nine SNPs, distrib-
uted across ALOX5AP, in the British cohort and searched for other
haplotypes that might be associated with myocardial infarction, two
SNPs showed association to myocardial infarction with a nominally
significant P value (data not shown). Moreover, three- and four-SNP
haplotype combinations were associated with higher risk of myocar-
dial infarction in the British cohort, and we observed the most signifi-
Figure 2  Pairwise LD between SNPs in a 60-kb region encompassing
ALOX5AP. The markers are plotted equidistantly. Two measures of LD are
shown: D ′ in the upper left triangle and P values in the lower right triangle.
Colored lines indicate the positions of the exons of ALOX5AP, and the green
stars indicate the location of the markers of the at-risk haplotype HapA.
Scales for both measures of the LD strength are provided on the right.
Table 1  Association of HapA with myocardial infarction, stroke and PAOD
Phenotype (n) Frequency RR PAR P value P valuea
Myocardial infarction (779) 0.158 1.80 0.135 0.0000023 0.005
Males (486) 0.169 1.95 0.158 0.00000091 ND
Females (293) 0.138 1.53 0.094 0.0098 ND
Early onset (358) 0.139 1.53 0.094 0.0058 ND
Stroke (702)b 0.149 1.67 0.116 0.000095 ND
Males (373) 0.156 1.76 0.131 0.00018 ND
Females (329) 0.141 1.55 0.098 0.0074 ND
PAOD (577)b 0.122 1.31 0.056 0.061 ND
Males (356) 0.126 1.36 0.065 0.057 ND
Females (221) 0.114 1.22 0.041 0.31 ND
aP value adjusted for the number of haplotypes tested. bExcluding known cases of myocardial infarction.
Shown is HapA of ALOX5AP and the corresponding number of affected individuals (n), the haplotype frequency in
affected individuals, the relative risk (RR), PAR and P values. HapA is defined by the SNPs SG13S25, SG13S114,
SG13S89 and SG13S32 (Supplementary Table 5 online). The same controls (n = 624) were used for the association
analysis in myocardial infarction, stroke and PAOD as well as for the analysis of males, females and individuals with
early onset. The frequency of HapA in the control cohort is 0.095. ND, not done.
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cant association for a four-SNP haplotype with a nominal P value of
0.00037 (Table 2). We call this haplotype HapB. The haplotype fre-
quency of HapB was 7.5% in the individuals with myocardial infarc-
tion (carrier frequency 14.4%) compared with 4.0% (carrier
frequency 7.8%) in controls, conferring a relative risk of 1.95 (Table
2). This association of HapB remained significant after adjusting for
all haplotypes tested, using 1,000 randomization steps, with an
adjusted P = 0.046. No other SNP haplotype had an adjusted P value
<0.05. The two at-risk haplotypes, HapA and HapB, are mutually
exclusive; there are no instances in which the same chromosome car-
ries both haplotypes.
More LTB4 in individuals with myocardial infarction
To determine whether individuals with a past history of myocardial
infarction had greater activity of the 5-LO pathway than controls, we
measured production of LTB4 (a key product of the 5-LO pathway)
in blood neutrophils isolated from Icelandic individuals with
myocardial infarction and controls before and after stimulation with
the calcium ionophore ionomycin. We detected no difference in
LTB4 production in resting neutrophils from
individuals with myocardial infarction ver-
sus controls. In contrast, LTB4 generation by
neutrophils stimulated with ionomycin was
substantially greater in individuals with
myocardial infarction than in controls after
15 and 30 min, respectively (Fig. 3a).
Moreover, the observed difference in release
of LTB4 was largely accounted for by male
carriers of HapA (Fig. 3b), whose cells pro-
duced significantly more LTB4 than cells
from controls (P = 0.0042; Supplementary
Table 7 online). There was also a heightened LTB4 response in males
who did not carry HapA, but this difference was of borderline signif-
icance (Supplementary Table 7 online). This could be explained by
additional variants in ALOX5AP that have not been uncovered, or in
other genes belonging to the 5-LO pathway, that may account for
upregulation of the LTB4 response in some individuals without the
ALOX5AP at-risk haplotype. We did not detect differences in LTB4
response in females (Supplementary Table 7 online), but because of
the small sample size, this result is not conclusive. The elevated levels
of LTB4 production in stimulated neutrophils from male carriers of
the at-risk haplotype suggest that the disease-associated variants of
ALOX5AP heighten the response of FLAP to factors that stimulate
inflammatory cells.
DISCUSSION
Our results show that variants of ALOX5AP encoding FLAP are asso-
ciated with greater risk of myocardial infarction and stroke. In our
Icelandic cohort, a haplotype that spans ALOX5AP is carried by
29.1% of all individuals with myocardial infarction and almost dou-
bles the risk of myocardial infarction. We then replicated these find-
ings in an independent cohort of individuals with stroke.
Furthermore, stimulated neutrophils from individuals with myocar-
dial infarction had greater production of LTB4, one of the key prod-
ucts of the 5-LO pathway. When we examined this in the context of
the at-risk haplotype, however, the gain of function was largely
attributed to male carriers of the at-risk haplotype, who also had the
strongest association with the ALOX5AP haplotype. Another haplo-
type spanning ALOX5AP was associated with myocardial infarction
in a British cohort. Although the pathogenic variants responsible for
the effects associated with the disease haplotypes are unknown, the
greater production of LTB4 observed in ionomycin-stimulated neu-
trophils from male carriers of the at-risk haplotype suggests that the
disease-associated variants increase the response of FLAP to factors
that stimulate inflammatory cells.
We observed suggestive linkage to chromosome 13q12–13 with
several different phenotypic groups, including females with myocar-
dial infarction, individuals of both sexes with early-onset myocardial
infarction and males with ischemic stroke or TIA. But we observed
the strongest haplotype association for males with myocardial
infarction or stroke. Therefore, the linkage signal in females with
myocardial infarction and in individuals with early-onset myocardial
infarction is not explained by the at-risk haplotype that we identi-
fied, and we expect that there may be other unidentified variants or
haplotypes in ALOX5AP, or in other genes in the linkage region, that
may confer risk of these cardiovascular phenotypes. These variants
are probably rarer than HapA with relatively high penetrance, higher
in women than in men.
FLAP has an important role in the initial steps of leukotriene
biosynthesis15, which is largely confined to leukocytes and can be
Figure 3  LTB4 production of ionomycin-stimulated neutrophils from
individuals with myocardial infarction (n = 41) and controls (n = 35). The log-
transformed (mean ± s.d.) values measured at 15 and 30 min in stimulated
cells are shown. (a) LTB4 production in individuals with myocardial infarction
(MI) and controls. The difference in the mean values between affected
individuals and controls was tested using a two-sample t-test of the log-
transformed values. (b) LTB4 production in males with myocardial infarction
carrying HapA (red bars) and not carrying HapA (white bars). Mean values of
controls (blue bars) are included for comparison. Males with HapA produced
the highest amounts of LTB4 (P < 0.005 compared with controls). Data for
females are shown in Supplementary Table 7 online.
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Table 2  Association of HapB with myocardial infarction in British individuals
Phenotype (n) Frequency RR PAR P value P valuea
Myocardial infarction (753) 0.075 1.95 0.072 0.00037 0.046
Males (549) 0.075 1.97 0.072 0.00093 ND
Females (204) 0.073 1.90 0.068 0.021 ND
aP value adjusted for the number of haplotypes tested using 1,000 randomization tests.
Shown are the results for HapB that shows the strongest association in the British myocardial infarction cohort. HapB
is defined by the SNPs SG13S377, SG13S114, SG13S41 and SG13S35, which have the alleles A, A, A and G,
respectively. In all three phenotypes shown, the same set of 730 British controls was used and the frequency of HapB
in the control cohort is 0.040. Number of affected individuals (n), haplotype frequency in affected individuals,
relative risk (RR) and PAR are indicated. ND, not done.
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triggered by a variety of stimuli. In this biosynthetic pathway, unes-
terified arachidonic acid is converted to LTA4 by the action of 5-LO
and its activating protein FLAP. The unstable epoxide LTA4 is fur-
ther metabolized to LTB4 or LTC4 by LTA4 hydrolase and LTC4 syn-
thase, respectively. In addition, LTA4 can be exported to
neighboring cells that are devoid of 5-LO activity and become sub-
ject to transcellular leukotriene biosynthesis21–23. The leukotrienes
have a variety of proinflammatory effects24,25. LTB4 activates leuko-
cytes, leading to chemotaxis and increased adhesion of leukocytes to
vascular endothelium, release of lysosomal enzymes such as
myeloperoxidase and production of superoxide anions25. The cys-
teinyl-containing leukotrienes (LTC4 and its metabolites LTD4 and
LTE4) increase vascular permeability in postcapillary venules and
are potent vasoconstrictors of coronary arteries26–28.
The importance of the 5-LO pathway is well established in
asthma, and drugs inhibiting this pathway have been developed for
treating asthma. The role of the 5-LO pathway in the pathogenesis
of atherosclerosis has recently received attention. A study of post-
mortem pathologic specimens showed an increase in the expression
of members of the 5-LO pathway, including 5-LO and FLAP, in ath-
erosclerotic lesions at various stages of development in the aorta,
coronary arteries and carotid arteries18. Furthermore, 5-LO was
localized to macrophages, dendritic cells, foam cells, mast cells and
neutrophilic granulocytes, and the number of cells expressing 5-LO
was markedly greater in advanced lesions18. The leukocytes positive
for 5-LO accumulated at distinct sites that are most prone to rup-
ture29, such as the shoulder regions below the fibrous cap of the ath-
erosclerotic lesion18. A 5-LO promoter variant is associated with
abnormal carotid artery intima-media thickness and heightened
inflammatory biomarkers30. In addition, antagonists of LTB4 block
the development of atherosclerosis in apo-E-deficient and LDRL-
deficient mice31, and a congenic mouse strain with a heterozygous
deficiency of 5-LO shows resistance to atherosclerosis16, further
supporting the idea that greater activity of the 5-LO pathway has a
role in predisposition to atherosclerosis.
Our data also show that the at-risk haplotype of ALOX5AP has
higher frequency in all subgroups of stroke, including ischemic stroke,
TIA and hemorrhagic stroke. HapA confers significantly higher risk of
myocardial infarction and stroke than it does of PAOD. This could be
explained by differences in the pathogenesis of these diseases. Unlike
individuals with PAOD, who have ischemic legs because of atheroscle-
rotic lesions that are responsible for gradually diminishing blood flow
to the legs, individuals with myocardial infarction and stroke have suf-
fered acute events, with disruption of the vessel wall suddenly decreas-
ing blood flow to regions of the heart and the brain.
We did not find association between HapA and myocardial infarc-
tion in a British cohort, but we did find significant association between
myocardial infarction and a different ALOX5AP variant. The existence
of different haplotypes of the gene conferring risk to myocardial
infarction in different populations is not unexpected. It is not unrea-
sonable to assume that a common disease like myocardial infarction is
associated with many different mutations or sequence variations and
that the frequencies of these disease-associated variants may differ
between populations. It would also not be unexpected for the same
mutation to arise on different haplotypic backgrounds.
Our work suggests that ALOX5AP has an important role in the
pathogenesis of myocardial infarction and stroke in humans. Our
study, together with others, may provide the necessary background to
launch therapeutic trials to determine whether pharmacological inhi-
bition of FLAP will prevent the development of myocardial infarction
and stroke.
METHODS
Study population. We recruited the individuals in the study from a registry of
over 8,000 individuals, which includes all individuals who had myocardial
infarctions before the age of 75 in Iceland from 1981 to 2000. This registry is a
part of the WHO MONICA Project19. Diagnoses of all individuals in the reg-
istry follow strict diagnostic rules based on signs, symptoms, electrocardio-
grams, cardiac enzymes and necropsy findings.
We used genotypes from 713 individuals with myocardial infarction and
1,741 of their first-degree relatives in the linkage analysis. For the microsatellite
association study of the locus associated with myocardial infarction, we used
802 unrelated (no first- or second-degree relatives) individuals with myocardial
infarction (233 females, 624 males and 302 with early onset) and 837 popula-
tion-based controls. The females studied were post-menopausal. Over 90% of
the individuals were taking aspirin or other nonsteroidal anti-inflammatory
drugs. For the SNP association study in and around ALOX5AP, we genotyped
779 unrelated individuals with myocardial infarction (293 females, 486 males
and 358 with early onset). The control group for the SNP association study was
population-based and comprised of 624 unrelated males and females 20–90
years of age whose medical history was unknown. The stroke and PAOD
cohorts used in this study have previously been described32–34. For the stroke
linkage analysis, we used genotypes from 342 males with ischemic stroke or TIA
that were linked to at least one other male within and including six meioses in
164 families. For the association studies, we analyzed 702 individuals with all
forms of stroke (329 females and 373 males) and 577 individuals with PAOD
(221 females and 356 males). Individuals with stroke or PAOD who also had
myocardial infarction were excluded. Controls used for the stroke and PAOD
association studies were the same as used in the myocardial infarction SNP
association study.
The study was approved by the Data Protection Commission of Iceland and
the National Bioethics Committee of Iceland. We obtained informed consent
from all study participants. Personal identifiers associated with medical infor-
mation and blood samples were encrypted with a third-party encryption sys-
tem as previously described35.
Statistical analysis. We carried out a genome-wide scan as previously
described33, using a set of 1,068 microsatellite markers. We used multipoint,
affected-only allele-sharing methods36 to assess the evidence for linkage. All
results were obtained using the program Allegro37 and the deCODE genetic
map38. We used the Spairs scoring function
39,40 and the exponential allele-shar-
ing model36 to generate the relevant 1-degree-of-freedom statistics. When
combining the family scores to obtain an overall score, we used a weighting
scheme that is halfway on a log scale between weighting each affected pair
equally and weighting each family equally. In the analysis, all genotyped indi-
viduals who were not affected were treated as ‘unknown’. Because of concern
with small-sample behavior, we usually computed corresponding P values in
two different ways for comparison and report the less significant one. The first
P value was computed based on large sample theory, Zlr = √(2 loge (10) lod), and
is distributed approximately as a standard normal distribution under the null
hypothesis of no linkage36. A second P value was computed by comparing the
observed lod score with its complete data sampling distribution under the null
hypothesis37. When a data set consisted of more than a handful of families,
these two P values tended to be very similar. The information measure we used,
which is implemented in Allegro, is closely related to a classical measure of
information and has a property that is between 0 (if the marker genotypes are
completely uninformative) and 1 (if the genotypes determine the exact amount
of allele sharing by descent among the affected relatives)41,42.
For single-marker association studies, we used Fisher’s exact test to calculate
two-sided P values for each allele. All P values are unadjusted for multiple com-
parisons unless specifically indicated. We present allelic rather than carrier fre-
quencies for microsatellites, SNPs and haplotypes. To minimize any bias due to
the relatedness of the individuals who were recruited as families for the linkage
analysis, we eliminated first- and second-degree relatives. For the haplotype
analysis we used the program NEMO32, which handles missing genotypes and
uncertainty with phase through a likelihood procedure, using the expectation-
maximization algorithm as a computational tool to estimate haplotype fre-
quencies. Under the null hypothesis, the affected individuals and controls were
assumed to have identical haplotype frequencies. Under the alternative
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hypotheses, the candidate at-risk haplotype was allowed to have a higher fre-
quency in the affected individuals than in controls, and the ratios of frequencies
of all other haplotypes were assumed to be the same in both groups.
Likelihoods were maximized separately under both hypotheses, and a corre-
sponding 1-degree-of-freedom likelihood ratio statistic was used to evaluate
statistical significance32. Although we only searched for haplotypes that
increased the risk, all reported P values are two-sided unless otherwise stated.
To assess the significance of the haplotype association corrected for multiple
testing, we carried out a randomization test using the same genotype data. We
randomized the cohorts of affected individuals and controls and repeated the
analysis. This procedure was repeated up to 1,000 times, and the P value we pre-
sent is the fraction of replications that produced a P value for a haplotype tested
that was lower than or equal to the P value we observed using the original
affected individual and control cohorts.
For both single-marker and haplotype analysis, we calculated relative risk
(RR) and PAR assuming a multiplicative model43,44 in which the risk of the two
alleles of haplotypes a person carries multiply. We calculated LD between pairs
of SNPs using the standard definition of D′ (ref. 45) and R2 (ref. 46). Using
NEMO, we estimated frequencies of the two marker allele combinations by
maximum likelihood and evaluated deviation from linkage equilibrium by a
likelihood ratio test. When plotting all SNP combinations to elucidate the LD
structure in a particular region, we plotted D′ in the upper left corner and the P
value in the lower right corner. In the LD plots we present, the markers are plot-
ted equidistantly rather than according to their physical positions.
Identification of DNA polymorphisms. We identified new polymorphic
repeats (dinucleotide or trinucleotide repeats) with the Sputnik program. We
subtracted the lower allele of the CEPH sample 1347-02 (CEPH genomics
repository) from the alleles of the microsatellites and used it as a reference. We
detected SNPs in the gene by PCR sequencing exonic and intronic regions from
affected individuals and controls. We also detected public polymorphisms by
BLAST search of the National Center for Biotechnology Information SNP data-
base. We genotyped SNPs using a method for detecting SNPs with fluorescent
polarization template-directed dye-terminator incorporation47 and TaqMan
assays (Applied Biosystems).
Isolation and activation of peripheral blood neutrophils. We drew 50 ml of
blood from each of 41 individuals with myocardial infarction and 35 age- and
sex-matched controls into vacutainers containing EDTA. All blood was drawn
at the same time in the early morning after 12 h of fasting. We isolated neu-
trophils using Ficoll-Paque PLUS (Amersham Biosciences).
We collected the red cell pellets from the Ficoll gradient and then lysed red
blood cells in 0.165 M ammonium chloride for 10 min on ice. After washing
them with phosphate-buffered saline, we counted neutrophils and plated them
at 2 × 106 cells ml–1 in 4-ml cultures of 15% fetal calf serum (GIBCO BRL) in
RPMI-1640 medium (GIBCO BRL). We then stimulated cells with maximum
effective concentration of ionomycin (1 µM). At 0, 15, 30, 60 min after adding
ionomycin, we aspirated 600 µl of culture medium and stored it at –80 °C for
the measurement of LTB4 release as described below. We maintained cells at 
37 °C in a humidified atmosphere of 5% carbon dioxide–95% air. We treated all
samples with indomethasine (1 µM) to block the cyclooxygenase enzyme.
Ionomycin-induced release of LTB4 in neutrophils. We used the LTB4
Immunoassay (R&D systems) to quantify LTB4 concentration in supernatant
from cultured ionomycin-stimulated neutrophils. The assay we used is based on
the competitive binding technique in which LTB4 present in the testing samples
(200 µl) competes with a fixed amount of alkaline phosphatase–labeled LTB4 for
sites on a rabbit polyclonal antibody. During the incubation, the polyclonal anti-
body becomes bound to a goat antibody to rabbit coated onto the microplates.
After washing to remove excess conjugate and unbound sample, a substrate solu-
tion was added to the wells to determine the bound enzyme activity. We stopped
the color development and read the absorbance at 405 nm. The intensity of the
color is inversely proportional to the concentration of LTB4 in the sample. Each
LTB4 measurement using the LTB4 Immunoassay was done in duplicate.
British study population. We recruited three separate British cohorts as
described previously48,49. The first two cohorts comprised 549 individuals from
among those who were admitted to the coronary care units of the Leicester
Royal Infirmary, Leicester (July 1993–April 1994), and the Royal Hallamshire
Hospital, Sheffield (November 1995–March 1997), and satisfied the WHO cri-
teria for acute myocardial infarction in terms of symptoms, elevations in car-
diac enzymes or electrocardiographic changes50. We recruited 532 control
individuals in each hospital from adult visitors of individuals with noncardio-
vascular disease on general medical, surgical, orthopedic and obstetric wards to
find subjects representative of the source population from which the affected
individuals originated. Individuals who reported a history of coronary heart
disease were excluded.
In the third cohort, we recruited 204 individuals retrospectively from the
registries of three coronary care units in Leicester. All had suffered a myocardial
infarction according to WHO criteria before the age of 50 years. At the time of
participation, individuals were at least 3 months from the acute event. The con-
trol cohort comprised 198 individuals with no personal or family history of
premature coronary heart disease, matched for age, sex and current smoking
status with the cases. We recruited control individuals from three primary care
practices located in the same geographical area. In all cohorts, individuals were
white of Northern European origin. Local research ethics committees approved
all the studies, and individuals provided written informed consent for use of
samples in genetic studies of coronary artery disease.
URLs. The Sputnik program is available at http://espressosoftware.com/pages/
sputnik.jsp. The National Center for Biotechnology Information SNP database
is available at http://www.ncbi.nlm.nih.gov/SNP/index.html.
Note: Supplementary information is available on the Nature Genetics website.
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